Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare ...
July 14 2020 - 7:00AM
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the
“Company”), a pioneering global biotech company committed to
accelerating commercialization and transforming the delivery of
cell and gene therapies (CGTs), today announces that it has entered
into a Collaboration Agreement with Educell Ltd., a premier
European cell therapy company. Under the agreement, the parties
plan to conduct one or more collaborative cell-based research
projects aligned with local medical centers.
The companies will leverage the Orgenesis Cell
and Gene Therapy (CGT) Biotech Platform which includes point of
care (POCare) Networks, POCare Therapeutics and a POCare
Technologies suite of proprietary and in-licensed technologies
that have been engineered to create customized processing systems.
The agreement is part of the Orgenesis strategy of growing and
expanding the POCare Network, which includes leading hospitals and
research institutes around the world. The first collaboration under
the agreement will focus on the clinical development of CAR-T and
whole cell-based vaccine platform for use in cancer
immunotherapies.
Vered Caplan, CEO of Orgenesis, stated, “This
latest collaboration with Educell expands our activities in Europe
and we believe that it should help us launch our therapies into
additional European hospitals, as well as help Educell
commercialize their therapies around the world. We also believe
that this collaboration reinforces the significant value
proposition and flexibility of our CGT Biotech Platform. We look
forward to benefiting from the expertise of Educell as we seek to
expand our automated T-cell culturing approach into clinical
validation and commercialization phases.”
Dr Miomir Knežević, CEO of Educell, commented,
“We are excited to team with Orgenesis to potentially advance these
breakthrough therapies into clinical trials using cutting edge
technologies. This collaboration reflects our commitment to
bringing new, effective and affordable cell and gene therapy
products to cancer patients worldwide while highlighting Educell’s
ability to ensure safety in the process and help to reduce overall
manufacturing costs.”
Together, the companies are working to address
significant unmet market needs for producing novel cell therapies
in a cost effective, high quality and scalable manner. The joint
clinical development program seeks to provide safe, simplified, and
cost-effective processing in an automated and controlled
environment from start to finish with minimal operator
intervention.
About EducellEducell Ltd,
established 1997, is a company focusing on the development of cell
therapy products and is a registered cell and tissue establishment.
The company is preparing cell therapy products for the treatment of
articular cartilage, vesicouretral reflux, regeneration of bone
tissue and treatment of immunological disorders, which are in use
within the University Medical Centre Ljubljana and other clinical
institutions in Slovenia under the “hospital exemption” rule
supervised by the Agency for Medicinal Products and Medical Devices
of the Republic of Slovenia. The company’s R&D department is
dedicated to the development of innovative cell therapy products
and also to the development of medical devices that enable stem
cell isolation and application in the operation theatre.
Educell’s ImmunoArt cell therapy product was
developed in 2014 and is based on ex vivo expanded allogeneic
mesenchymal stromal/stem cells (MSC) isolated from bone marrow. Its
immunomodulatory capacity has already been proven in the clinic for
the treatment of graft versus host disease (GvHD) and Chron’s
disease. Additional information is available at:
https://www.educell.si/en/
About OrgenesisOrgenesis is a
pioneering global biotech company which is unlocking the full
potential of personalized therapies and closed processing systems
through its Cell & Gene Therapy Biotech Platform, with the
ultimate aim of providing life changing treatments at the Point of
Care to large numbers of patients at low cost. The Platform
consists of: (a) POCare Therapeutics, a pipeline
of licensed cell and gene therapies (CGTs), and proprietary
scientific knowhow; (b) POCare Technologies, a
suite of proprietary and in-licensed technologies which are
engineered to create customized processing systems for affordable
point of care therapies; and (c) POCare Network, a
collaborative, international ecosystem of leading research
institutes and hospitals committed to clinical development and
supply of CGTs at the point of care. By combining science,
technologies and a collaborative network, Orgenesis is able to
identify the most promising new therapies and provide a pathway for
them to reach patients more quickly, more efficiently and at scale,
thereby unlocking the power of cell and gene therapy for all.
Additional information is available at: www.orgenesis.com.
Notice Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements which are made pursuant to the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended. These
forward-looking statements involve substantial uncertainties and
risks and are based upon our current expectations, estimates and
projections and reflect our beliefs and assumptions based upon
information available to us at the date of this release. We caution
readers that forward-looking statements are predictions based on
our current expectations about future events. These forward-looking
statements are not guarantees of future performance and are subject
to risks, uncertainties and assumptions that are difficult to
predict. Our actual results, performance or achievements could
differ materially from those expressed or implied by the
forward-looking statements as a result of a number of factors,
including, but not limited to, our reliance on, and our ability to
grow, our point-of-care cell therapy platform, our ability to
effectively use the net proceeds from the sale of Masthercell, our
ability to achieve and maintain overall profitability, the
development of our POCare strategy, the sufficiency of working
capital to realize our business plans, the development of our
transdifferentiation technology as therapeutic treatment for
diabetes which could, if successful, be a cure for Type 1 Diabetes;
our technology not functioning as expected; our ability to retain
key employees; our ability to satisfy the rigorous regulatory
requirements for new procedures; our competitors developing better
or cheaper alternatives to our products and the risks and
uncertainties discussed under the heading "RISK FACTORS" in Item 1A
of our Annual Report on Form 10-K for the fiscal year ended
December 31 2019, and in our other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or update
any forward-looking statement for any reason.
Contact for Orgenesis:Crescendo
Communications, LLCTel: 212-671-1021Orgs@crescendo-ir.com
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Sep 2023 to Sep 2024